TAFS – The impact of COVID-19 on food safety and global health

17 August 2021 | Technical news (commented)

The extent to which the COVID-19 pandemic has had an impact on food safety and the control of other infectious diseases both in people and in animals globally is becoming more evident. There have been short-term impacts such as the suspension of routine activities as well as long-term impacts such as the stimulation of industries and organizations to act and collaborate in the name of global health resilience.


Read the entire article here
TAGS food safety, covid-19

New TAFS White Paper on Campylobacter

11 January 2019 | Position Papers

The TAFS forum has published a new White Paper entitled "Campylobacter - The role of poultry meat in Campylobacter epidemiology and mitigation measures along the food chain".

The aim of this paper is to present a fair appraisal of the current knowledge regarding epidemiology and intervention measures along the poultry food chain and to provide guidance for risk management decisions. It is not intended to promote or endorse any particular intervention strategy.

See for more details.

Read the entire article here
TAGS TAFS, position paper, food safety, campylobacter

RedHill BioPharma has positive results from anti-MAP Crohn’s disease trial

22 August 2018 | Technical news (uncommented clippings)

First reported by Reuters, Tel Aviv, July 30:

Israel's RedHill Biopharma said on Monday it had positive safety and efficacy results from a late-stage clinical trial with its treatment for Crohn's disease called RHB-104.

The study met its primary endpoint and key secondary endpoints, demonstrating the drug's superiority over a placebo in achieving remission of the gastrointestinal disease at week 26, the company said in a statement. 

"The proportion of patients meeting the primary endpoint was significantly greater in the RHB-104 group compared to placebo," RedHill said. 

Patients treated with RHB-104 also experienced a statistically significant benefit in achieving early remission at week 16 and in durable remission over weeks 16-52. 

RHB-104 was found to be generally safe and well tolerated, said the company, which is focused on proprietary drugs for gastrointestinal diseases. 

"Many patients with Crohn’s disease do not achieve remission on current standard-of-care therapies, which are accompanied with poor side effects," said David Graham, lead investigator of the Phase III study. 

"RHB-104 appears to have the potential to become a promising, new, orally administered therapy for this important debilitating disease." 

RHB-104 is a proprietary, antibiotic combination therapy that is based on the hypothesis that Crohn’s disease is caused by a bacterial infection in susceptible patients called Mycobacterium avium subspecies paratuberculosis (MAP). 

Comment [by; highlighting by TAFS]: If the final published results of this trial are consistent with the claims in this press release, it represents a final piece of evidence indicating that MAP is a cause of Crohn’s disease. This would heighten the need for veterinary medicine, animal agriculture, and relevant governmental agencies concerned with food safety to limit contamination of food and water by MAP.

Read the entire article here
TAGS TAFS, technical news, paratuberculosis, MAP, food safety, Crohn's
By threads

Monthly Archive


Oct Aug


Nov Apr




Oct Aug Jun


Dec Nov Oct Sep


Dec Mar


Aug Jul May Feb


Dec Jan


Aug May Apr Mar Jan


Dec Nov Oct Aug Apr Jan




If you are not a member of the TAFS forum you may subscribe to our news stream. You will not be able to see some the news in full (for members only), but we aim to share as much as possible publicly. Just enter your email address: